肺癌耐药蛋白与Ⅲ期非小细胞肺癌新辅助化疗的关系及临床意义

Relationship between expression of lung resistance-related protein (LRP) and neoadjuvant chemotherapy in stage Ⅲ non-small cell lung cancer and its clinical significance

目的 :探讨肺癌耐药蛋白的表达与Ⅲ期非小细胞肺癌 (NSCLC)新辅助化疗敏感性及预后的关系。方法 :应用免疫组化技术检测 3 1例进行新辅助化疗的患者化疗前标本。结果 :化疗前LRP表达的阳性率为 3 8 7% ( 12 / 3 1)。化疗前LRP表达阳性者化疗有效率为 16 7% ( 2 / 12 )。LRP表达阳性的患者中位生存期为 14个月 ,阴性的为 2 5个月 ,但差异无统计学意义 ,P>0 0 5。结论 :对于可手术切除的Ⅲ期NSCLC而言 ,肿瘤中LRP表达阳性者化疗耐药的可能性很大 ,该类患者应放弃或减少新辅助化疗周期。LRP表达阳性者预后可能不良。

OBJECTIVE:To investigate the expression of lung resistance-related protein in stage Ⅲ non-small cell lung cancer (NSCLC) and evaluate its clinical significance. METHODS:Samples from 31 patients with NSCLC before neoadjuvant chemotherapy were examined by the immunohistochemistry technique.RESULTS:The positive rate of LRP was 38.7% before neoadjuvant chemotherapy. The respond rate to chemotherapy was 16.7%(2/12)in which LRP was positive before chemotherapy. The median survival time of the patients with and without positive expression of LRP was 14 months and 25 months respectively,but having no significant difference,P>0.05.CONCLUSIONS:If the expression of LRP is detected the cycle of neoadjuvant chemotherapy should be given up or reduced in order to improve the survival rate.The prognosis may be poor if the expression of LRP is positive.